244 related articles for article (PubMed ID: 32233322)
41. Cell clonality in hypereosinophilic syndrome: what pathogenetic role?
Galimberti S; Ciabatti E; Ottimo F; Rossi A; Trombi L; Carulli G; Cervetti G; Matti L; Bianchi G; Petrini M
Clin Exp Rheumatol; 2007; 25(1):17-22. PubMed ID: 17417985
[TBL] [Abstract][Full Text] [Related]
42. The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases.
La Starza R; Specchia G; Cuneo A; Beacci D; Nozzoli C; Luciano L; Aventin A; Sambani C; Testoni N; Foppoli M; Invernizzi R; Marynen P; Martelli MF; Mecucci C
Haematologica; 2005 May; 90(5):596-601. PubMed ID: 15921374
[TBL] [Abstract][Full Text] [Related]
43. [Current differential diagnosis of hypereosinophilic syndrome].
Dinić-Uzurov V; Lalosević V; Milosević I; Urosević I; Lalosević D; Popović S
Med Pregl; 2007; 60(11-12):581-6. PubMed ID: 18666600
[TBL] [Abstract][Full Text] [Related]
44. Hypereosinophilic syndromes and new therapeutic approaches including anti-IL-5.
Stein ML; Rothenberg ME
Expert Rev Clin Immunol; 2005 Nov; 1(4):633-44. PubMed ID: 20477604
[TBL] [Abstract][Full Text] [Related]
45. Eosinophils and eosinophil-associated disorders: immunological, clinical, and molecular complexity.
Valent P; Degenfeld-Schonburg L; Sadovnik I; Horny HP; Arock M; Simon HU; Reiter A; Bochner BS
Semin Immunopathol; 2021 Jun; 43(3):423-438. PubMed ID: 34052871
[TBL] [Abstract][Full Text] [Related]
46. Clinical Profile and Treatment in Hypereosinophilic Syndrome Variants: A Pragmatic Review.
Requena G; van den Bosch J; Akuthota P; Kovalszki A; Steinfeld J; Kwon N; Van Dyke MK
J Allergy Clin Immunol Pract; 2022 Aug; 10(8):2125-2134. PubMed ID: 35470096
[TBL] [Abstract][Full Text] [Related]
47. Primary eosinophilic disorders: a concise review.
Pardanani A; Tefferi A
Curr Hematol Malig Rep; 2008 Jan; 3(1):37-43. PubMed ID: 20425445
[TBL] [Abstract][Full Text] [Related]
48. Hypereosinophilic syndrome: approach to treatment in the era of precision medicine.
Klion A
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):326-331. PubMed ID: 30504328
[TBL] [Abstract][Full Text] [Related]
49. Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics.
Roche-Lestienne C; Lepers S; Soenen-Cornu V; Kahn JE; Laï JL; Hachulla E; Drupt F; Demarty AL; Roumier AS; Gardembas M; Dib M; Philippe N; Cambier N; Barete S; Libersa C; Bletry O; Hatron PY; Quesnel B; Rose C; Maloum K; Blanchet O; Fenaux P; Prin L; Preudhomme C
Leukemia; 2005 May; 19(5):792-8. PubMed ID: 15772698
[TBL] [Abstract][Full Text] [Related]
50. [Diagnosis of non-parasitic hypereosinophilia].
Kahn JE; Girszyn N; Blétry O
Presse Med; 2006 Jan; 35(1 Pt 2):144-52. PubMed ID: 16462679
[TBL] [Abstract][Full Text] [Related]
51. Treatment of hypereosinophilic syndromes--the first 100 years.
Butterfield JH; Weiler CR
Semin Hematol; 2012 Apr; 49(2):182-91. PubMed ID: 22449628
[TBL] [Abstract][Full Text] [Related]
52. Hypereosinophilic syndrome and proliferative diseases.
Ionescu MA; Wang L; Janin A
Acta Dermatovenerol Croat; 2009; 17(4):323-30. PubMed ID: 20021987
[TBL] [Abstract][Full Text] [Related]
53. Eosinophilia in Hematologic Disorders.
Falchi L; Verstovsek S
Immunol Allergy Clin North Am; 2015 Aug; 35(3):439-52. PubMed ID: 26209894
[TBL] [Abstract][Full Text] [Related]
54. Hypereosinophilic syndrome: an update.
Wilkins HJ; Crane MM; Copeland K; Williams WV
Am J Hematol; 2005 Oct; 80(2):148-57. PubMed ID: 16184589
[TBL] [Abstract][Full Text] [Related]
55. [The idiopathic hypereosinophilic syndrome and chronic eosinophilic leukemia].
Chrobák L; Voglová J
Vnitr Lek; 2005 Dec; 51(12):1385-93. PubMed ID: 16430106
[TBL] [Abstract][Full Text] [Related]
56. Clinical and Biological Markers in Hypereosinophilic Syndromes.
Khoury P; Makiya M; Klion AD
Front Med (Lausanne); 2017; 4():240. PubMed ID: 29312946
[TBL] [Abstract][Full Text] [Related]
57. [Practical approach to hypereosinophilia].
Roufosse F; Cogan E
Rev Med Brux; 2008 Sep; 29(4):400-8. PubMed ID: 18949995
[TBL] [Abstract][Full Text] [Related]
58. A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome.
Salemi S; Yousefi S; Simon D; Schmid I; Moretti L; Scapozza L; Simon HU
Allergy; 2009 Jun; 64(6):913-8. PubMed ID: 19210352
[TBL] [Abstract][Full Text] [Related]
59. Successful treatment of idiopathic hypereosinophilic syndrome with imatinib mesylate: a case report.
Tan D; Hwang W; Ng HJ; Goh YT; Tan P
Int J Hematol; 2004 Jul; 80(1):75-7. PubMed ID: 15293573
[TBL] [Abstract][Full Text] [Related]
60. How I treat hypereosinophilic syndromes.
Klion AD
Blood; 2015 Aug; 126(9):1069-77. PubMed ID: 25964669
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
